Sopharma AD notifies that for April 2015 the Company recorded an increase of sales revenues of 2% compared to the same month of 2014, including 8% increase of domestic sales and 1% decrease of export sales.

For the four months of this year, revenues from sales decreased by 15% compared to the same period of 2014, including 16% increase of domestic sales and a 28% decrease of export sales.

Sopharma AD notifies that for March 2015 the Company recorded a decrease of sales revenues of 7% compared to the same month of 2014, including 32% increase of domestic sales and 21% decrease of export sales.

For the three months of this year, revenues from sales decreased by 21% compared to the same period of 2014, including 20% increase of domestic sales and a 35% decrease of export sales.

In March 2015 the subsidiary of Sopharma AD, Sopharma Ukraine EOOD, with a core business in trading with pharmaceutical products, increased its capital to 317 531 502 UAH.

The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from 27 September 2012 up to and including 3 October 2012 the Company bought 600 own shares representing 0.00045% of the share capital of the Company, to the total value of BGN 1445.4 on the Bulgarian Stock Exchange. The average price per share was BGN 2.41.

The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.

SOPHARMA AD hereby informs that from 26 March 2015 up to and including 1 April 2015 the Company bought 664 own shares representing 0.00049% of the share capital of the Company, at a total value of 2310.8 BGN on the Bulgarian Stock Exchange, the average price per share was 3.48 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 163 820, representing 3.83% of the share capital of the Company.

The Board of Directors of Sopharma AD (the “Company”) notifies that for September 2012 sales revenues remained at the same level compared to the same period of 2011, including 9% decrease of domestic sales and 4% increase of export sales.

During the first nine months of this year Sopharma AD realized an increase of sales revenues of 2%, including 10% decrease of domestic sales and 7% increase of export sales compared to the same period of 2011.

Sopharma AD (the “Company”) announces that on 5 March 2015 the Company bought 605 000 shares from the capital of Medika AD. After this transaction, the share of Sopharma AD in the capital of Medika AD increased to 30.42%.

Sopharma AD informs that the Board of Directors of Sopharma AD authorized the Executive Director of the company to undertake negotiations for the sale of the shares of Extab Corporation owned by Sopharma AD.

Sopharma AD informs that today Sopharma reached an agreement for the sale of 75% of the capital of Extab Corporation. After the transaction Sophama will remain a shareholder in the company with 5%.

SOPHARMA AD hereby informs that from 14 May 2015 up to and including 20 May 2015 the Company bought 3312 own shares representing 0.0025% of the share capital of the Company, at a total value of 10 274.19 BGN on the Bulgarian Stock Exchange, the average price per share was 3.10 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 167 132, representing 3.83% of the share capital of the Company.

SOPHARMA AD hereby informs that from 21 May 2015 up to and including 27 May 2015 the Company bought 2000 own shares representing 0.0015% of the share capital of the Company, at a total value of 6 130.00 BGN on the Bulgarian Stock Exchange, the average price per share was 3.07 BGN.

The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.

The total number of treasury shares after these transactions is 5 169 132, representing 3.83% of the share capital of the Company.